46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency

46,XY difference of sex development (DSD) with adrenal insufficiency due to CYP11A1 deficiency is an extremely rare autosomal recessive disorder caused by mutations in the CYP11A1 gene, which encodes the cholesterol side-chain cleavage enzyme (also known as P450scc). This enzyme catalyzes the first and rate-limiting step in steroidogenesis — the conversion of cholesterol to pregnenolone — which is the precursor for all steroid hormones including cortisol, aldosterone, and sex steroids. The condition is also known as lipoid congenital adrenal hyperplasia (lipoid CAH) due to CYP11A1 deficiency, or P450 side-chain cleavage enzyme deficiency. It is distinct from the more common form of lipoid CAH caused by StAR protein deficiency, though the clinical presentations overlap significantly. Because all steroid hormone synthesis is impaired, affected individuals present with severe adrenal insufficiency, typically in the neonatal period, manifesting as salt-wasting crises with hyponatremia, hyperkalemia, dehydration, and potentially life-threatening adrenal crises. In 46,XY individuals, the inability to produce testosterone during fetal development results in undervirilization, leading to female or ambiguous external genitalia despite having a male karyotype — hence the classification as a 46,XY difference of sex development. The gonads may show lipid accumulation due to the inability to convert cholesterol. 46,XX individuals are also affected by adrenal insufficiency but typically have normal female external genitalia, though they will not undergo spontaneous puberty. Treatment is lifelong and centers on hormone replacement therapy, including glucocorticoid replacement (such as hydrocortisone) to address cortisol deficiency and mineralocorticoid replacement (such as fludrocortisone) to manage aldosterone deficiency. Sex steroid replacement is required at the expected age of puberty. Early diagnosis and prompt initiation of treatment are critical to prevent fatal adrenal crises. Gender assignment and psychosocial support are important components of management for affected 46,XY individuals. With appropriate hormonal replacement and monitoring, patients can have improved outcomes, though lifelong medical follow-up is essential.

Common questions about 46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency